Cycurion, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CYCU$2.470.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(2,561,786) | $(10,248,486) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 315,833 | - |
| Stock-based compensation - business combination related | - | 9,250,000 |
| Amortization of debt discount | 1,187 | 64,850 |
| Depreciation of property and equipment | - | 1,709 |
| Amortization of software development costs | - | 8,333 |
| Gain on debt settlement, net | - | (141,653) |
| Finance expense | - | 100,000 |
| Changes in assets and liabilities: | ||
| Accounts receivable, net and other receivables | (648,568) | (1,300,686) |
| Prepaid expenses and other current assets | (46,801) | (11,415) |
| Accounts payable and accrued liabilities | (184,201) | (286,114) |
| Accrued compensation and benefits | 96,248 | 37,673 |
| Accrued interest payable | 138,254 | (219,320) |
| Net cash used in operating activities | (2,889,834) | (2,745,109) |
| Cash flows from investing activities: | ||
| Cash acquired on business combination | - | 34,983 |
| Capitalized software development costs | (129,000) | (70,000) |
| Cash withdrawn from Trust Account in connection with redemption | - | 1,001,216 |
| Release of Trust Account to Company's bank account | - | 833,324 |
| Net cash (used in)/provided by investing activities | (129,000) | 1,799,523 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of warrants | 167 | 3,309,921 |
| Redemption of common stock subject to redemption | - | (1,001,216) |
| Repayments of revolving line of credit | (207,850) | (9,300) |
| Repayment of bank borrowings | - | (5,114) |
| Proceeds from convertible notes payable | - | 386,500 |
| Proceeds from notes payable | - | 513,200 |
| Repayments of notes payable | - | (20,000) |
| Net cash (used in)/provided by financing activities | (207,683) | 3,173,991 |
| Net (decrease)/increase in cash and cash equivalents | (3,226,517) | 2,228,405 |
| Cash and cash equivalents, beginning of period | 5,255,235 | 40,790 |
| Cash and cash equivalents, end of period | $2,028,718 | $2,269,195 |
| See accompanying notes to unaudited consolidated financial statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.